Global Biopharmaceuticals Contract Manufacturing Market

Biopharmaceuticals Contract Manufacturing Market Size, Share, Growth Analysis, By Source(Mammalian, Non-mammalian), By Service(Process Development, Fill & Finish Operations, Packaging, others), By Product Type(Interferon, Monoclonal Antibodies, Protein, Vaccines), By Therapeutic Applications(Oncology, Cardiovascular Diseases, Others), By Region - Industry Forecast 2025-2032


Report ID: SQSG35H2019 | Region: Global | Published Date: April, 2024
Pages: 157 | Tables: 120 | Figures: 77

Biopharmaceuticals Contract Manufacturing Market Insights

Biopharmaceuticals Contract Manufacturing Market size was valued at USD 17.88 Billion in 2023 and is poised to grow from USD 18.81 Billion in 2024 to USD 29.69 Billion by 2032, growing at a CAGR of 5.2% during the forecast period (2025-2032).

The reduction in the investment required to developed new drug product, providing access to highly expensive technologies, greater flexibility, and fast entry of newly innovated products into the global market, are the key factors anticipated to drive the growth of the global biopharmaceuticals contract manufacturing market during the forecast period. For instance, Thermo Fisher Scientific announced about their investment of USD 180 million for constructing a new commercial manufacturing facility in Plainville. The new production facility will enable company to increase its production capacity and allow to fulfill growing consumer demand.

Furthermore, high technological advancements and introduction to new innovations in bioprocessing has paved a way in the progress and development of various contract service providers around the globe by overcoming from several manufacturing concerns like high production cost and need to changeover with every batch. Moreover, acquisitions, mergers, and increasing joint ventures among key market players of the global market has resulted in high growth and demand for these services globally. For instance, in March 2021, Baxter International Inc., has entered into an agreement with Baxter BioPharma Solutions for providing fill/finish sterile manufacturing solutions and supply packaging for around 60-90 million doses of the Moderna COVID-19 vaccine in the year 2021.

US Biopharmaceuticals Contract Manufacturing Market is poised to grow at a sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Biopharmaceuticals Contract Manufacturing Market size was valued at USD 17 billion in 2019 and is poised to grow from USD 17.88 billion in 2023 to USD 28.22 billion by 2031, growing at a CAGR of 5.2% in the forecast period (2024-2031).

biopharmaceuticals contract manufacturing market is consolidated in nature with the presence of several large market players operating across the globe. And, in terms of market share, top 5 players of the market are dominating the market including Boehringer Ingelheim, JSR Pharma, and Inno Biologics Sdn Bhd. These players are highly focusing on few business developing strategies including collaborations, mergers, new product innovations, and advance technology adoption to expand their geographical presence and product offerings. 'Boehringer Ingelheim GmbH', 'Catalent', 'Lonza Group AG', 'Thermo Fisher Scientific Inc.', 'Samsung BioLogics Co. Ltd.', 'Fujifilm Diosynth Biotechnologies', 'WuXi Biologics (Cayman) Inc.', 'AbbVie Inc.', 'AGC Biologics', 'Baxter BioPharma Solutions', 'Biocon Ltd.', 'Cytovance Biologics Inc.', 'Eurofins Scientific SE', 'Genscript Biotech Corporation', 'Grifols SA', 'Innovent Biologics (Suzhou) Co. Ltd.', 'JSR Corporation', 'KBI Biopharma Inc.', 'Merck KGaA', 'Novasep Holding SAS'

Increasing Demand for Biological Therapies

Introduction of AI Boosting Biopharmaceuticals Contract Manufacturing Market Growth

Globally, North America region dominated the biopharmaceuticals contract manufacturing with a holding of strong market share in 2021 due to the large number of biomanufacturing facilities in the United States. Additionally, interventions & conferences conducted in the North America for pertinent developing technologies and major issues in applications of biologics for the better treatment of several chronic disorders are likely to fuel the adoption of contract manufacturing services in the region over the coming years.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Biopharmaceuticals Contract Manufacturing Market

Report ID: SQSG35H2019

$5,300
BUY NOW GET FREE SAMPLE